Skip to main content

Icosavax, Inc.

ICVXDelisted Feb 20, 2024
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001786255

Icosavax, Inc. was delisted on Feb 20, 2024; its insiders filed their last Form 4 on Feb 20, 2024; 93 institutions reported holding it in 13F filings for Q4 2023, worth $663.0M in total; no superinvestor held it.

Currency
USD
Source
SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
Updated
Oct 8, 2026, 2:18 PM ET

Revenue flow, FY2022

Where the revenue went in FY2022, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.

Net loss for FY2022: $91.8M (15766.0% of revenue).

Income statement

Each column is one fiscal year, newest first.

Income statement of Icosavax, Inc., annual
Line itemFY2022FY2021
Period endDec 31, 2022Dec 31, 2021
Filing10-K10-K
ReportedMar 30, 2023Jan 7, 2022
Revenue$582.0K$7.80M
Operating expenses$95.6M$73.7M
Research and development$65.4M$38.8M
Selling, general and administrative$30.2M$34.9M
Operating income-$95.1M-$65.9M
Interest expense–$263.0K
Net income-$91.8M-$67.0M
EPS, basic$-2.31–
EPS, diluted$-2.31–
Weighted shares, basic39.7M–
Weighted shares, diluted39.7M–
Margins and growth
Operating margin-16333.0%-844.2%
Net margin-15766.0%-858.4%
Revenue growth, year over year−92.5%–

Balance sheet

Each column is one fiscal year, newest first.

Balance sheet of Icosavax, Inc., annual
Line itemFY2022FY2021
Period endDec 31, 2022Dec 31, 2021
Filing10-K10-K
ReportedMar 30, 2023Jan 7, 2022
Cash and equivalents$58.8M$279.1M
Short-term investments$159.5M–
Total current assets$223.9M$286.6M
Property, plant and equipment$11.5M$1.08M
Total assets$238.7M$287.6M
Total current liabilities$13.8M$9.24M
Total liabilities$20.5M$9.41M
Shareholders' equity$218.2M$278.2M

Cash flow statement

Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.

Cash flow statement of Icosavax, Inc., annual
Line itemFY2022FY2021
Period endDec 31, 2022Dec 31, 2021
Filing10-K10-K
ReportedMar 30, 2023Jan 7, 2022
Operating cash flow-$61.7M-$38.5M
Capital expenditures$11.1M$1.01M
Free cash flow-$72.8M-$39.5M
Stock-based compensation$21.7M$29.0M
Investing cash flow-$169.4M-$1.01M
Financing cash flow$10.3M$304.8M
Ratio
Stock-based compensation, % of revenue3727.5%372.1%

Shares outstanding

Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.

Shares outstanding for Icosavax, Inc. by cover date
Cover dateShares outstandingChange in a yearFiling
Nov 8, 202350.1M+25.5%SEC
Aug 8, 202350.0M+25.5%SEC
May 3, 202341.4M+4.3%SEC
Mar 21, 202341.4M+4.2%SEC
Nov 7, 202239.9M+2.2%SEC
Aug 9, 202239.9M+1.3%SEC
May 9, 202239.7M–SEC
Mar 28, 202239.7M–SEC

Notes and known gaps

How these numbers are put together, and what they can't tell you.

  • Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
  • Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.

Known gaps

  • Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
  • EPS and share counts are as reported at the time, not adjusted for later stock splits.
  • For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
  • For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
  • Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
  • Depreciation and amortization is missing for some companies that report it under their own XBRL tags.